Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Table 1

Baseline characteristics of all subjects.

	Control	Pretreatment
Clinical characteristics
(male/female)	20 (16/4)	20 (17/3)	1.000
Age (years)			0.676
Weight (kg)			0.128
BMI (kg/m^2)			0.188
Waist circumference (cm)			<0.001
Biochemical and metabolic parameters
FBG (mmol/L)			<0.001
2 hPBG (mmol/L)			<0.001
FINS (μU/ml)			<0.001
HOMA-IR			<0.001
HbA1c (%)			<0.001
TCH (mmol/L)			<0.001
HDL (mmol/L)			<0.001
LDL (mmol/L)			0.113
TG (mmol/L)			0.016
ALT (U/L)			0.004
AST (U/L)			0.03
ALP (U/L)			0.100
GGT (U/L)			0.002
FGF21 (pg/ml)			<0.001
Liver fat content (%)			<0.001

Abbreviations: BMI: body mass index; FBG: fasting blood glucose; 2 hPBG: 2-hour postprandial blood glucose; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance; HbA1c: glycated hemoglobin; TC: total cholesterol; HDL: high-density lipoprotein cholesterol; TG: triglyceride; LDL: low-density lipoprotein cholesterol; ALT: alanine amino transferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: γ-glutamyl transferase; FGF21: fibroblast growth factor 21. ; .